Amarantus Bioscience Holdings Inc (AMBS)

[breezy1]

In a study entitled "MANF Inhibits Tau Hyperphosphorylation in Cultured Neuronal Cells" published in the journal Chinese Pharmacological Bulletin, the authors demonstrated that MANF had a pronounced effect in reducing tau hyperphosphorylation, reducing cell death, and improving overall cellular health in a preclinical models. Misfolded tau is a significant part of the pathophysiology of Alzheimer's disease and Chronic Traumatic Encephalopathy (CTE). The data in the study demonstrated:

Pretreatment with recombinant MANF can inhibit okadaic acid (OA) induced tau hyperphosphorylation in N2a cells;
Transfection of N2a cell with MANF cDNA also inhibits OA-induced tau hyperphosphorylation and supports cell viability;
Downregulation of MANF with siRNA promotes OA-induced toxicity.
In a study entitled "MANF Is Indispensable for the Proliferation and Survival of Pancreatic ß Cells" published in the journal Cell, the authors demonstrated that MANF is essential for the protection and proliferation of pancreatic beta islet cells. Beta islet cells degenerate via apoptosis in Type-1 Diabetes, Type-2 Diabetes and Wolfram Syndrome. The data in the study demonstrate:

MANF-deficient mice show growth retardation and a diabetic phenotype;
Beta cell mass is significantly reduced in MANF KO mice, caused by decreased proliferation and increased apoptosis;
Recombinant MANF significantly increases beta cell proliferation in vitro, while overexpression of MANF in the pancreas of diabetic mice enhances beta cell regeneration.
"The underlying mechanism of MANF appears to be truly unique, breakthrough biology with the potential to alter the practice of medicine in various large, underserved medical applications worldwide," said David A. Lowe, PhD and member of the Amarantus Board of Directors. "These two papers are particularly striking, given the emerging evidence for overlap in mechanisms involved in Alzheimer's disease and Diabetes. They provide further support for our work and raise the spectrum of future clinical developments, alongside Retinitis Pigmentosa and Parkinson's disease, into which our current development activities with MANF could feed. We are currently focused on the translation of this tremendous biological opportunity into clinical development and are making steady progress in this regard. We are encouraged the worldwide research community continues to increase the value of our IP position by publishing such important work and is conducting much of the proof of concept work related to this fascinating molecule as we move towards clinical trials."

http://globenewswire.com/news-release/2014/05/01/632354/10079549/en/Amarantus-Announces-Positive-Independent-Peer-Reviewed-Preclinical-Data-for-MANF-in-Alzheimer-s-and-Diabetes.html?print=1

That's why you buy a million shares.